0.00Open0.04Pre Close0 Volume249 Open Interest86.00Strike Price0.00Turnover76.46%IV14.03%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0154Delta0.0054Gamma2499.75Leverage Ratio-0.0310Theta-0.0001Rho-38.43Eff Leverage0.0036Vega
Merck & Co Stock Discussion
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...
This is probably why the market is retreating a little bit.
That said, I believe the Fed will still proceed with its expected 25 basis point rate cut next week because other inflation data over the past few months are showing that it is trending downwards.
$Vanguard S&P 500 ETF (VOO.US)$ $KraneShares CSI China Internet ETF (KWEB.US)$ $First Republic Bank (FRCB.US)$ $Crude Oil Futures(FEB5) (CLmain.US)$ $Goldman Sachs (GS.US)$ $Citigroup (C.US)$ $ChargePoint (CHPT.US)$ $LivePerson (LPSN.US)$ $Clover Health (CLOV.US)$ $Vanguard Growth ETF (VUG.US)$ $JD.com (JD.US)$ $Baidu (BIDU.US)$ $FuboTV (FUBO.US)$ $Merck & Co (MRK.US)$ $The Trade Desk (TTD.US)$
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...
No comment yet